-
Mashup Score: 51ClinicalTrials.gov - 2 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 188Lipoprotein(a) Associated Molecules are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis - PubMed - 3 day(s) ago
The LPA gene is the only monogenetic risk factor for calcific aortic valve stenosis (CAVS). Oxidized phospholipids (OxPL) and lysophosphatidic acid generated by autotaxin (ATX) from OxPL are pro-inflammatory. Aortic valve leaflets were categorized pathologically from Both ATX-apoB and ATX-apo …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet-
Yes-https://t.co/lXTdpjyLCs https://t.co/1DRidd2g4Q https://t.co/YwwZfsPnrv
-
-
Mashup Score: 51ClinicalTrials.gov - 3 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, CardiologistsTweet-
No Phase 3 Lp(a) HORIZON started in 2019, and is estimated to read out in 2025. We are almost there...https://t.co/WPN2GejTKH https://t.co/GU4VjeIPnX https://t.co/FZ6zvdbZMW
-
-
Mashup Score: 182Lipoprotein(a) Associated Molecules are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis - PubMed - 3 day(s) ago
The LPA gene is the only monogenetic risk factor for calcific aortic valve stenosis (CAVS). Oxidized phospholipids (OxPL) and lysophosphatidic acid generated by autotaxin (ATX) from OxPL are pro-inflammatory. Aortic valve leaflets were categorized pathologically from Both ATX-apoB and ATX-apo …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet-
Yes-https://t.co/lXTdpjyLCs https://t.co/1DRidd2g4Q https://t.co/YwwZfsPnrv
-
-
Mashup Score: 58
ClinicalTrials.gov Identifier: NCT05563246.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet-
There is now data on @OxPL_apoB and OxPL-apo(a) with oral muvalaplin Lp(a) drug (measured @UCSDCardiology). @UCSDCardFellows https://t.co/TcFtUzyzHP https://t.co/e7CSR7db9U
-
-
Mashup Score: 58
ClinicalTrials.gov Identifier: NCT05563246.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet-
There is now data on @OxPL_apoB and OxPL-apo(a) with oral muvalaplin Lp(a) drug (measured @UCSDCardiology). @UCSDCardFellows https://t.co/TcFtUzyzHP https://t.co/e7CSR7db9U
-
-
Mashup Score: 22High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low - 10 day(s) ago
While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.
Source: www.tctmd.comCategories: General Medicine News, CardiologistsTweet-
Here is an interview on the paper @TCTMD It is more suited for lay audience, so good source for interpreting the data. @hsbhatia https://t.co/ojwEQ7Xuof https://t.co/lUFXvoplZd
-
-
Mashup Score: 3
We are entering an era of gene-based drug approaches that will revolutionize our ability to treat patients with atherosclerotic cardiovascular disease, enabling earlier and more effective interventions. In this EAS webinar, we will examine recent data on RNA-targeting strategies in lipid management and explore therapies based on genome editing with CRISPR/Cas9. Although these treatments are still in development, they hold significant promise for patients with severe dyslipidemias and atherosclerosis. Join us to gain invaluable insights and practical knowledge from two world-renowned experts in the field!
Source: us02web.zoom.usCategories: General Medicine News, CardiologistsTweet-
RT @society_eas: 🚨 Only 2 hours left before the webinar starts! This is your last chance to register and join us: https://t.co/h3YhwwpIc8.…
-
-
Mashup Score: 41
Novartis Pharma AG.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet-
This graph is theoretical, and we need to wait for Lp(a) outcomes trials before we know if the depiction of the arrows is accurate. All evidence to date is Lp(a)-mediated risk is not modifiable by treating other risk factors. See https://t.co/d0txGcA2gs https://t.co/eD5xeDR2k7
-
-
Mashup Score: 1Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial - PubMed - 22 day(s) ago
ClinicalTrials.gov Identifier: NCT04472676.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet-
Muvalaplin from Lilly. https://t.co/3xd0IY3Ddq However, until we know where the free apo(a) with its OxPL cargo goes or if it gets into vessels easier, for me, the jury is out if this will be safe and effective. https://t.co/dN5UwUAeKw
-
No Phase 3 Lp(a) HORIZON started in 2019, and is estimated to read out in 2025. We are almost there...https://t.co/WPN2GejTKH https://t.co/GU4VjeIPnX https://t.co/FZ6zvdbZMW